How Investors May Respond To Cooper (COO) Earnings Miss

• Cooper Companies recently completed a broad review of its portfolio and leadership, decided to retain CooperSurgical, reported detailed third quarter results, issued fourth quarter 2026 guidance, and continued sizeable share repurchases.
• Jana Partners has publicly urged Cooper Companies to replace its CEO, change board leadership, and reconsider asset sales after the review that did not produce a transaction for CooperSurgical.
• We will now look at how Cooper Companies' investment narrative is affected by the earnings reset and Jana Partners' activist letter.

Use this reset at Cooper Companies as a prompt to scan for other healthcare groups that combine resilient balance sheets with cleaner growth stories through our curated list of solid balance sheet and fundamentals (23 results)

Cooper Companies Investment Narrative Recap

To own Cooper Companies, you need to be comfortable with a story that revolves around steady contact lens demand, a cleaner execution path for MyDAY and MiSight, and a more volatile fertility and IUD franchise inside CooperSurgical. The recent guidance reset and Jana’s letter sharpen attention on execution rather than changing the core lens thesis, while index removal creates more technical than business pressure.

The most important near term catalyst is visible improvement in organic growth at CooperVision as MyDAY transitions and channel inventories settle. The biggest risk sits in prolonged softness or pricing pressure across both lenses and fertility, which could keep revenue growth closer to the low single digit range and limit operating leverage.

The completed strategic review on September 10 is the key backdrop for everything that followed. Cooper Companies kept CooperSurgical after bids that the board viewed as unattractive given temporary issues around a rival non hormonal IUD and fertility litigation. That decision keeps fertility and contraception firmly tied to the equity story rather than spinning off near term complexity.

Keeping CooperSurgical means execution in that unit now matters as much as any governance change Jana is pushing for. Progress on fertility volumes, PARAGARD procedure trends and the MyDAY rollout will likely shape how quickly sentiment can repair after the index removal and the 2026 outlook cut, especially with share repurchases already sizable and free cash flow an important part of the appeal.

Cooper Companies' current analyst narrative points to revenues of $4.9b and earnings of $782.6m by 2029, anchored on 4.7% yearly revenue growth and an earnings increase of about $212m from $570.3m today.

Uncover why Cooper Companies' fair value indicates a 22% potential upside to its current price, before valuation gaps at Cooper Companies may narrow.

Exploring Other Perspectives

Analysts who focus on Cooper Companies’ contact lens pipeline see product launches as a key swing factor. Before this Jana letter and the index exit, the most optimistic group was modelling revenue of about $5.0b and earnings near $929.9m by 2029. That is far above the baseline view and shows how widely opinions can spread. Use this gap as a cue to compare several narratives, especially now that the news flow may reshape forecasts.

Explore 5 other Cooper Companies fair value estimates, including one that suggests potential upside of as much as 128% from the current price!

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Cooper Companies research is our analysis highlighting 4 key rewards that could impact your investment decision.
• See our latest analysis for Cooper Companies. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Cooper Companies' overall financial health at a glance.

Looking for more investment ideas beyond Cooper Companies?

Use the reset at Cooper Companies as a springboard to widen your watchlist and stress test your thesis against other opportunities using the Simply Wall St Screener.

• If you want potential upside with a margin of safety, start with a focused group of 29 high quality undervalued stocks that pair supportive fundamentals with discounted prices.
• If capital preservation matters just as much as returns for you, filter for 30 resilient stocks with low risk scores and see which businesses show stronger resilience on core risk checks.
• If you are hunting for tomorrow's leaders before the crowd pays attention, scan through 16 high quality undiscovered gems with solid financial underpinnings but limited current coverage.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com